Praxgen Pharmaceuticals

Praxgen Pharmaceuticals, founded in 2016 and headquartered in San Diego with key operations in New Jersey, is a private, commercial-stage generic drug developer. The company has a strategic focus on complex generics, with over 40 products in development and a track record of ANDA approvals and product launches, such as generic Medrol and Fosaprepitant. Leveraging a hybrid model of in-house R&D and external manufacturing partnerships, Praxgen aims to capture value in high-barrier, high-market-size generic drug segments while navigating the competitive and regulatory pressures inherent to the industry.

Integrated development and regulatory expertise for complex generic drug products (ophthalmics, injectables, topicals, oral solids), utilizing a hybrid model of in-house R&D and a network of contract manufacturing partners.

Praxgen competes in the generic pharmaceuticals sector against large, diversified generics manufacturers (e.g., Teva, Mylan/Viatris, Sun Pharma) and other specialty generics companies focused on complex dosage forms. Its success depends on out-executing competitors in developing difficult-to-formulate products and navigating regulatory pathways faster to achieve favorable market positioning.